Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Abstract Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration a...

Full description

Bibliographic Details
Main Authors: Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June, Michael R. Bishop
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Chimeric antigen receptor
Tisagenlecleucel
Axicabtagene ciloleucel
Leukemia
Lymphoma
Online Access:http://link.springer.com/article/10.1186/s40425-018-0460-5

Internet

http://link.springer.com/article/10.1186/s40425-018-0460-5

Similar Items